These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27539851)

  • 21. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The plasma membrane Ca
    Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A
    Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.
    Audrito V; Managò A; La Vecchia S; Zamporlini F; Vitale N; Baroni G; Cignetto S; Serra S; Bologna C; Stingi A; Arruga F; Vaisitti T; Massi D; Mandalà M; Raffaelli N; Deaglio S
    J Natl Cancer Inst; 2018 Mar; 110(3):. PubMed ID: 29309612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.
    Salas Fragomeni RA; Chung HW; Landesman Y; Senapedis W; Saint-Martin JR; Tsao H; Flaherty KT; Shacham S; Kauffman M; Cusack JC
    Mol Cancer Ther; 2013 Jul; 12(7):1171-9. PubMed ID: 23615632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of
    Aloia A; Müllhaupt D; Chabbert CD; Eberhart T; Flückiger-Mangual S; Vukolic A; Eichhoff O; Irmisch A; Alexander LT; Scibona E; Frederick DT; Miao B; Tian T; Cheng C; Kwong LN; Wei Z; Sullivan RJ; Boland GM; Herlyn M; Flaherty KT; Zamboni N; Dummer R; Zhang G; Levesque MP; Krek W; Kovacs WJ
    Clin Cancer Res; 2019 Nov; 25(22):6852-6867. PubMed ID: 31375515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
    Phadke MS; Sini P; Smalley KS
    Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
    Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
    Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BIF-1 inhibits both mitochondrial and glycolytic ATP production: its downregulation promotes melanoma growth.
    Frangež Ž; Fernández-Marrero Y; Stojkov D; Seyed Jafari SM; Hunger RE; Djonov V; Riether C; Simon HU
    Oncogene; 2020 Jun; 39(26):4944-4955. PubMed ID: 32493957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Local histone acetylation by ACSS2 promotes gene transcription for lysosomal biogenesis and autophagy.
    Li X; Qian X; Lu Z
    Autophagy; 2017 Oct; 13(10):1790-1791. PubMed ID: 28820290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
    Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
    J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simulation of the metabolism of absorbed energy-yielding nutrients in young sheep: efficiency of utilization of acetate.
    Black JL; Gill M; Beever DE; Thornley JH; Oldham JD
    J Nutr; 1987 Jan; 117(1):105-15. PubMed ID: 3819858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of SLC25A11 causes suppression of NSCLC and melanoma tumor formation.
    Lee JS; Lee H; Lee S; Kang JH; Lee SH; Kim SG; Cho ES; Kim NH; Yook JI; Kim SY
    EBioMedicine; 2019 Feb; 40():184-197. PubMed ID: 30686754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.
    Garay T; Kenessey I; Molnár E; Juhász É; Réti A; László V; Rózsás A; Dobos J; Döme B; Berger W; Klepetko W; Tóvári J; Tímár J; Hegedűs B
    PLoS One; 2015; 10(2):e0117021. PubMed ID: 25646931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HBx regulates fatty acid oxidation to promote hepatocellular carcinoma survival during metabolic stress.
    Wang MD; Wu H; Huang S; Zhang HL; Qin CJ; Zhao LH; Fu GB; Zhou X; Wang XM; Tang L; Wen W; Yang W; Tang SH; Cao D; Guo LN; Zeng M; Wu MC; Yan HX; Wang HY
    Oncotarget; 2016 Feb; 7(6):6711-26. PubMed ID: 26744319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.
    Jenkins MH; Brinckerhoff CE; Mullins DW
    PLoS One; 2015; 10(3):e0121140. PubMed ID: 25798946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The natural product mensacarcin induces mitochondrial toxicity and apoptosis in melanoma cells.
    Plitzko B; Kaweesa EN; Loesgen S
    J Biol Chem; 2017 Dec; 292(51):21102-21116. PubMed ID: 29074620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathway identification combining metabolic flux and functional genomics analyses: acetate and propionate activation by Corynebacterium glutamicum.
    Veit A; Rittmann D; Georgi T; Youn JW; Eikmanns BJ; Wendisch VF
    J Biotechnol; 2009 Mar; 140(1-2):75-83. PubMed ID: 19162097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes.
    Demigné C; Morand C; Levrat MA; Besson C; Moundras C; Rémésy C
    Br J Nutr; 1995 Aug; 74(2):209-19. PubMed ID: 7547838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization.
    Lim JH; Luo C; Vazquez F; Puigserver P
    Cancer Res; 2014 Jul; 74(13):3535-45. PubMed ID: 24812272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.